- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Atomoxetine hydrochloride, Guanfacine hydrochloride (TAK-503), Placebo
- Drug · Other
- Lead sponsor
- Shire
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 396 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 20
- States / cities
- Dothan, Alabama • Anaheim, California • Imperial, California + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 76
matching trials from the local directory fallback.
Local D1 index available.
- Conditions
- Attention Deficit Hyperactivity Disorder, Posttraumatic Stress Disorder
- Interventions
- RFPP, TFCBT
- Behavioral
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 9 Years to 18 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- SPN-812
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 161 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- ADHD, ADHD - Combined Type, Attention Deficit Hyper Activity, Attention Deficit Hyperactivity Disorder, Attention Deficit Hyperactivity Disorder Combined, Attention-deficit Hyperactivity
- Interventions
- CTx-1301-Dexmethylphenidate 12.5 mg (titration only), CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose), Placebo
- Drug
- Lead sponsor
- Cingulate Therapeutics
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 24
- States / cities
- Jacksonville, Florida • Maitland, Florida • Orlando, Florida + 21 more
- Conditions
- Attention Deficit/Hyperactivity Disorder, Inattention
- Interventions
- Care as usual, Resource Navigation, Resource Packet, Screening
- Other
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Boston, Massachusetts
- Conditions
- ADHD, Attention Deficit Hyperactivity Disorder
- Interventions
- Other
- Behavioral
- Lead sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
- Other
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 312 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- ADHD, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder, Attention Deficit Hyperactivity Disorder Combined
- Interventions
- CTx-1301 - Dexmethylphenidate 25mg, CTx-1301 - Dexmethylphenidate 37.5mg, CTx-1301 - Dexmethylphenidate 50mg, Placebo
- Drug
- Lead sponsor
- Cingulate Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Placebo, SPN-810
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 38
- States / cities
- Culver City, California • Orange, California • Colorado Springs, Colorado + 33 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Placebo, Solriamfetol 150 MG, Solriamfetol 75 MG
- Other · Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- SPN-812
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 38
- States / cities
- Beverly Hills, California • Garden Grove, California • Los Alamitos, California + 33 more
- Conditions
- Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder, Sleep Disturbance
- Interventions
- Bedtime Bank, Melatonin
- Behavioral · Dietary Supplement
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Daily Report Card, School as Usual
- Behavioral · Other
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 5 Years to 14 Years
- Enrollment
- 211 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Placebo, mixed amphetamine salts-extended release (MAS-XR)
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 153 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Attention Deficit/Hyperactivity Disorder
- Interventions
- Adhansia XR
- Drug
- Lead sponsor
- Purdue Pharma LP
- Industry
- Eligibility
- 4 Years to 12 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 15
- States / cities
- Little Rock, Arkansas • Colorado Springs, Colorado • Jacksonville, Florida + 12 more
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- Adhansia XR, Concerta
- Drug
- Lead sponsor
- Purdue Pharma LP
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 35
- States / cities
- Dothan, Alabama • Beverly Hills, California • Cromwell, Connecticut + 31 more
- Conditions
- ADD, ADHD, ADHD - Combined Type, ADHD Predominantly Inattentive Type, ADHD, Predominantly Hyperactive - Impulsive, Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, Attention-Deficit Disorder in Adolescence, Attention-Deficit Hyperactivity Disorder, Attention-Deficit Hyperactivity Disorder Symptoms
- Interventions
- Digital Health Application (Online Platform) for Encouraging Skills Practice, Homework Organization and Planning Skills (HOPS) Intervention
- Device · Behavioral
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 11 Years to 14 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Broad Spectrum Micronutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants, Placebo
- Combination Product · Dietary Supplement
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 135 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 2
- States / cities
- Columbus, Ohio • Portland, Oregon
- Conditions
- Attention Deficit Hyperactivity Disorder, Dyslexia
- Interventions
- Atomoxetine, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 10 Years to 16 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- ADHD, Attention-Deficit/Hyperactivity Disorder
- Interventions
- Placebo, TD-9855
- Drug
- Lead sponsor
- Theravance Biopharma
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 295 participants
- Timeline
- 2011 – 2013
- U.S. locations
- 17
- States / cities
- Bradenton, Florida • Jacksonville, Florida • Maitland, Florida + 13 more
- Conditions
- Adherence, Medication, Attention Deficit Hyperactivity Disorder
- Interventions
- Mehealth for ADHD software with medication continuity tools, Mehealth for ADHD software with no medication continuity tools
- Other
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 11 Years to 15 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Attention-Deficit Hyperactivity Disorder (ADHD)
- Interventions
- PDC-1421 Capsule
- Drug
- Lead sponsor
- BioLite, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- HLD200 methylphenidate hydrochloride (MPH) Capsules, Placebo
- Drug
- Lead sponsor
- Ironshore Pharmaceuticals and Development, Inc
- Other
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 125 participants
- Timeline
- 2015 – 2016
- U.S. locations
- 7
- States / cities
- Newport Beach, California • Bradenton, Florida • Maitland, Florida + 4 more
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- Atomoxetine Hydrochloride, Lisdexamfetamine Dimesylate
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 34
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • Colton, California + 31 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Dasotraline, Placebo Comparator
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 43
- States / cities
- Dothan, Alabama • National City, California • Paramount, California + 37 more